Foundayo vs. Rybelsus®: What’s the Difference Between Oral GLP-1 Medications?

The oral GLP-1 space has grown quickly, and it’s easy to feel overwhelmed or confused by all the options. This may be especially true when it comes to Foundayo vs Rybelsus®.

Foundayo and Rybelsus® are approved for different conditions. Rybelsus® is a type 2 diabetes medication. Foundayo is a chronic weight management medication. They contain different active ingredients, and they’re taken very differently.

This article explains what each pill is, how they work, how they’re taken, and what the clinical data shows—plus where a third oral option, oral Wegovy®, fits in. 

‍

What Is a GLP-1 Medication? And Why Does the “Oral” Part Matter?

GLP-1 receptor agonists mimic a hormone called glucagon-like peptide-1 (GLP-1), which your body naturally releases after you eat. This hormone helps regulate blood sugar, slows gastric emptying (the rate at which food moves from your stomach into your small intestine), and helps reduce appetite.

For years, most GLP-1 medications were injections. Ozempic®, Wegovy®, Mounjaro®, and Zepbound® are all available as injectable medications, and oral GLP-1 pills are a newer, still-evolving category.

But there’s a technical reason injections came first. Many GLP-1 medications are peptides (protein-based molecules), and the digestive enzymes in your gut break peptides down before they can be absorbed. But Rybelsus® and Foundayo address oral delivery in two different ways, shaping how each one is taken.

‍

What Is Rybelsus®?

Rybelsus® is a brand-name oral medication containing semaglutide, which is the same active ingredient found in Ozempic® (an injection for type 2 diabetes) and Wegovy® (which is available in injectable and oral forms for weight management).

Rybelsus® is FDA-approved to improve blood sugar control in adults with type 2 diabetes, used alongside diet and exercise, and to reduce the risk of major cardiovascular events, such as heart attack, stroke, or cardiovascular death, in adults with type 2 diabetes who have a high cardiovascular risk.

To be clear, Rybelsus® is not FDA-approved for weight management in adults who don’t have type 2 diabetes.

‍

How Rybelsus® Is Taken

Rybelsus® has strict dosing requirements. It must be taken on an empty stomach with no more than 4 ounces (120 mL) of plain water, followed by a 30-minute wait before eating, drinking anything else, or taking other oral medications.

Since semaglutide is a peptide that would otherwise be broken down in the stomach, Rybelsus® is co-formulated with an absorption enhancer called SNAC (salcaprozate sodium) that helps the medication pass through the stomach lining. But this process only works well under these specific conditions. And even then, only roughly 0.4%-1% of each dose is absorbed.

However, this 30-minute fasted window can be a challenge for someone with a busy morning or a stack of other medications to take. For some individuals, the practicality of it may be something to discuss with your healthcare provider.

‍

Rybelsus® Dosing and Weight Loss Data

Rybelsus® is available in 3 mg, 7 mg, and 14 mg tablets. Individuals typically start at 3 mg for about 30 days, then move to 7 mg, with 14 mg as the maximum.

In type 2 diabetes trials, Rybelsus® at 14 mg was associated with reductions in body weight, with the amount varying across clinical trials and patient populations. For someone managing diabetes, this may be a meaningful secondary benefit. But keep in mind that this dose range was designed for blood sugar management, not obesity treatment, and the weight change observed is a secondary effect rather than the actual primary goal of the medication. 

‍

What Is Foundayo?

Foundayo is a brand-name oral medication containing orforglipron, approved by the FDA on April 1, 2026. So, how do orforglipron vs oral semaglutide compare?

Orforglipron is a GLP-1 receptor agonist like semaglutide, but it belongs to a structurally different class; it’s a small-molecule, non-peptide compound. 

Simply put, it isn’t built from protein chains the way semaglutide is, so it isn’t broken down by digestive enzymes in the same way—which is why it can work as a straightforward once-daily pill. 

Foundayo is FDA-approved for chronic weight management in adults with obesity (BMI ≥ 30), or in adults who are overweight (BMI ≥ 27) with at least one weight-related condition such as high blood pressure, high cholesterol, or obstructive sleep apnea. It’s used alongside a reduced-calorie diet and increased physical activity. 

Additionally, Foundayo is not currently FDA-approved for type 2 diabetes in the US, though its manufacturer, Eli Lilly, has said it plans to seek that indication.

‍

How Foundayo Is Taken

Foundayo can be taken once daily at any time of day, with or without food, and with any amount of water.

In other words, it does not require the same 30-minute fasted dosing window as Rybelsus®. Dosing starts low, at 0.8 mg once daily, and is increased gradually (generally every 30 days) up to a maximum of 17.2 mg. Foundayo comes in six tablet strengths, and this gradual step-up gives your body time to adjust and is intended to reduce the risk of gastrointestinal adverse reactions during dose escalation.

‍

Foundayo Clinical Trial Data

In the Phase 3 ATTAIN-1 trial, adults with obesity taking the highest approved dose of orforglipron lost an average of about 12.4% of their body weight at 72 weeks, compared with roughly 0.9% for placebo.

To put that in context, a 12.4% reduction for someone weighing 220 pounds works out to about 27 pounds. However, individual results vary, and Foundayo is intended to be used alongside lifestyle changes.

‍

Foundayo vs. Rybelsus®: Key Differences at a Glance

‍

What About Oral Wegovy? The Third Oral GLP-1 Option

In December 2025, the FDA approved a higher-dose oral semaglutide tablet (25 mg) under the brand name Wegovy® for chronic weight management. This was the first oral GLP-1 approved specifically for chronic weight management in the US.

Oral Wegovy contains the same active ingredient as Rybelsus® (semaglutide), but at a much higher dose and with a different approved use. In the OASIS 4 trial, oral semaglutide 25 mg was associated with about 16.6% mean weight loss at 64 weeks among participants who stayed on treatment, and about 13.6% when measured across all participants regardless of adherence.

Oral Wegovy and Foundayo are oral GLP-1 options approved for chronic weight management. Because these results come from separate clinical trials with different designs and populations, the percentages should not be interpreted as a head-to-head comparison. A licensed provider can help determine which option, if any, is appropriate for you and your situation. 

‍

Side Effects: What to Expect From Oral GLP-1 Medications

Since Foundayo and Rybelsus® both act on the GLP-1 receptor, they share several common gastrointestinal effects. The most common side effects reported with these medications include nausea, vomiting, diarrhea, constipation, and abdominal discomfort. These may occur during treatment, including during dose escalation, and should be discussed with a healthcare provider if they are severe or persistent.

For Foundayo, nausea has been reported in roughly 26%-35% of patients, constipation in about 20%-27%, diarrhea in about 21%-25%, and vomiting in about 13%-24%. For Rybelsus®, nausea has been reported in roughly 11%-20%, diarrhea in about 9%-10%, and constipation in about 5%-6%. Your healthcare provider can advise you on ways to manage any gastrointestinal side effects. 

‍

Important Safety Warnings

Foundayo and Rybelsus® each have important warnings and precautions, although their labeling is not identical: 

• Both carry a boxed warning concerning the potential risk of thyroid C-cell tumors and are contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). The human relevance of thyroid C-cell tumor findings associated with GLP-1 receptor activity in animals has not been determined. 
• Pancreatitis (inflammation of the pancreas).
• Gallbladder problems.
• Kidney issues, which may be linked to dehydration from GI side effects.
• Low blood sugar, particularly when combined with insulin or certain medications that increase insulin secretion. 
• Serious allergic reactions.

These are not all of the warnings, precautions, or possible side effects associated with either medication. A licensed provider will review your health history and other medications before prescribing. Review the applicable prescribing information and seek medical attention as directed for serious or unusual symptoms.

‍

Who Is Each Medication For? Eligibility Considerations

Rybelsus® is for adults with type 2 diabetes who need help managing blood sugar. It may offer secondary weight benefits, but it isn’t FDA-approved for chronic weight management. 

Foundayo is for adults with obesity (BMI ≥ 30), or overweight adults (BMI ≥ 27) with at least one weight-related condition, who are looking for chronic weight management support.

Either way, eligibility for any GLP-1 medication requires a consultation with a licensed healthcare provider who reviews your medical history, current medications, and goals. 

If you're wondering whether you may qualify, checking your BMI can offer a reasonable starting point.

‍

Exploring Oral Weight Loss Options Through a Telehealth Provider

If you’re interested in oral weight loss medications—GLP-1 based or otherwise—a telehealth provider can help you evaluate whether you’re eligible, weigh your options, and build a plan that is appropriate for your life.

Eden connects you with a licensed provider who reviews your health profile and determines what treatment options, if any, may be clinically appropriate based on your individual health information. Our process starts with a brief online intake. Eden’s weight loss options include both injectable and oral formats, and our provider-guided path is designed to make sure any prescription is clinically appropriate for you.